Safety and management of new primary melanomas during receipt of BRAF inhibitors.

[1]  L. Thomas,et al.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. , 2014, The Journal of investigative dermatology.

[2]  D. Schadendorf,et al.  Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Hauschild,et al.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Nagai,et al.  Vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[5]  J. Lott.  Vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[6]  S. Menzies,et al.  Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting , 2008, The British journal of dermatology.